Antitumor efficacy of lidamycin against human multiple myeloma RPMI 8226 cells and the xenograft in nonobese diabetic/severe combined immunodeficiency mice.

Autor:	Yongzhan Zhen, Boyang Shang, Xiujun Liu, Yajun Lin, Yongsu Zhen, Zhen, Yongzhan, Shang, Boyang, Liu, Xiujun, Lin, Yajun, Zhen, Yongsu
Předmět:	ANTINEOPLASTIC agents MYELOMA proteins XENOGRAFTS PEOPLE with diabetes APOPTOSIS ALKENES AMINOGLYCOSIDES ANIMAL experimentation CELL lines CELL physiology COMPARATIVE studies GENES RESEARCH methodology MEDICAL cooperation MICE MULTIPLE myeloma PROTEOLYTIC enzymes RESEARCH EVALUATION research
Zdroj:	Journal of Cancer Research & Therapeutics; Jan-Mar2016, Vol. 12 Issue 1, p182-187, 6p
Abstrakt:	Aims: The aim of this study is to explore the antitumor efficacy of lidamycin (LDM) against human multiple myelomas (MM).Materials and Methods: Human MM RPMI 8226 cells and the xenograft model in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice were used to examine the antitumor activity of LDM.Results: Notably, LDM markedly suppressed the growth of human MM RPMI 8226 xenograft in NOD/SCID mice. In vitro, there was a significant reduction in cell proliferation after treatment with LDM. The overall growth inhibition correlated with the increase of apoptotic cells. The apoptosis-related proteins including caspase-3, 7, and 9 were activated, and poly adenosine diphosphate-ribose polymerase was cleaved. Further investigation revealed that cellular Bcl-2 and survivin decreased, whereas the level of Bax increased in the LDM-treated cells.Conclusions: LDM is highly effective against the growth of MM xenograft in NOD/SCID mice. The potent apoptosis.inducing effect of LDM may be mediated through caspase. and mitochondria.dependent pathway. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu